摘要
基因编辑技术可针对性增强体细胞的靶向性,一定程度上解决了传统过继性免疫疗法在肿瘤等多种疾病治疗中显露出的靶向性差等问题。最具代表性的是嵌合抗原受体T细胞(CAR-T)免疫疗法,其在血液系统肿瘤治疗中已取得良好疗效,此外,T细胞受体基因工程化的T细胞(TCR-T)、基因修饰的树突状细胞以及基因修饰的干细胞在多种疾病治疗的临床研究中也显现了良好的安全性和有效性。目前国内外多家研究机构和生物公司已在基因修饰体细胞行业加速布局,相关产业即将进入快速发展期,基因修饰体细胞疗法的临床转化应用具有广阔前景,对目前已经开展疾病临床研究的几种基因修饰免疫细胞疗法进行总结。
The Gene editing technology could enhance the on-target of somatic cells,and partially resolve the problem of off-target of the adoptive immunotherapy in the treatment of tumors and the other diseases.One of the he most representative methods is CAR-T cell therapy,which has been achieved well curative effect in the treatment of hematological tumors.In addition,the treatment methods which include using TCR-T cells,genetically modified dendritic cells and genetically modified stem cells have also been shown well safety and effectiveness in the clinical research of various diseases.In view of this,many research institutions and biological companies in China and the other countries have accelerated their deployment in the fields of genetically modified somatic cell at now,and will be reaching a period of rapid development.The clinical transformation and application of genetically modified somatic cell therapy hold great promising in the fulture.
作者
王征旭
游嘉
武立华
童春容
吴迪
刘彩霞
昌晓红
程洪艳
程金莲
王少华
曹彩
马洁
WANG Zhengxu;YOU Jia;WU Lihua;TONG Chunrong;WU Di;LIU Caixia;CHANG Xiaohong;CHENG Hongyan;CHENG Jinlian;WANG Shaohua;CAO Cai;MA Jie(Seventh Medical Center of Chinese PLA General Hospital,Beijing 100700,China;Beijing Boren Hospital,GoBroad Medical Institute of Hematology,GoBroad Healthcare Group,Beijing 100070,China;Center of Biotherapy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Peking University People's Hospital,Beijing 100044,China;Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China;Zhongguancun Jiutai Good Clinical Practice Union,Beijing 100101,China)
出处
《药物评价研究》
CAS
2021年第2期250-264,共15页
Drug Evaluation Research
基金
国家科技重大专项课题——重大新药创制(2016ZX09101094)
北京市科委企业技术创新平台建设(Z181100000518028)。
